CCL22 and neoplasm: In a study by Coletta et al., mononuclear monocytes cultured together with tumor cells or decellularized tumor matrix differentiated into a pro-tumoral macrophage phenotype, characterized by decreased expression of MHC-II and CD86, increased expression of CD206, and abundant release of pro-tumoral cytokines (e.g., IL-6, IL-10, TGF-β) and chemokines (e.g., CCL17, CCL18, and CCL22).